VERTAVIS
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VERTAVIS (VERTAVIS).
Vertavis is an inhibitor of acetylcholinesterase, increasing acetylcholine levels at cholinergic synapses.
| Metabolism | Primarily hydrolyzed by plasma esterases; minor hepatic metabolism via CYP450 enzymes. |
| Excretion | Approximately 70% of the dose is excreted renally as unchanged drug and 30% via biliary/fecal routes as metabolites. |
| Half-life | Terminal elimination half-life is 39–58 hours (mean 49 hours), supporting once-daily dosing. Steady state is achieved after 7–10 days. |
| Protein binding | Approximately 99% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution is 0.4–0.6 L/kg (approx 30–50 L in adults), indicating distribution primarily into extracellular fluid. |
| Bioavailability | Oral bioavailability is approximately 50% (range 30–70%) with food reducing rate but not extent of absorption. |
| Onset of Action | Oral: Clinical effect (reduction in pulmonary arterial pressure) observed within 2–4 weeks of initiating therapy. |
| Duration of Action | Duration of therapeutic effect is 24 hours with once-daily dosing; sustained hemodynamic improvements noted with chronic therapy. |
5 mg orally three times daily. May be increased to 10 mg three times daily if tolerated.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (eGFR <30 mL/min/1.73 m²), use is not recommended. |
| Liver impairment | Not recommended for use in patients with moderate to severe hepatic impairment (Child-Pugh class B or C). No data available. |
| Pediatric use | Safety and efficacy not established; no recommended dose. |
| Geriatric use | No specific dose adjustment; use with caution due to potential increased sensitivity and comorbidities. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for VERTAVIS (VERTAVIS).
| Breastfeeding | Contraindicated during breastfeeding. No data on presence in human milk; however, animal studies show drug and metabolites are excreted in milk. M/P ratio not known. Due to potential for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment and for at least 3 weeks after last dose. |
| Teratogenic Risk | Contraindicated in pregnancy. FDA Pregnancy Category X. In animals, ribociclib (active ingredient) caused embryotoxicity, fetotoxicity, and teratogenicity at maternal exposures below human clinical exposure at 400 mg/day. First trimester: high risk of major congenital malformations; second and third trimesters: risk of fetal growth restriction and fetal death. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Hypersensitivity to Vertavis or any component","History of severe cholinergic adverse effects"]
| Precautions | ["Cardiovascular effects (bradycardia, syncope)","Gastrointestinal effects (nausea, vomiting, diarrhea)","Seizures","Weight loss"] |
Loading safety data…
| Fetal Monitoring | Pre-treatment: pregnancy testing within 7 days prior to initiation. During therapy: monitor for neutropenia (complete blood counts before each cycle, weekly for first 2 cycles, then before each cycle; dose interruptions may be required), QT prolongation (ECG before initiation and monitor electrolytes, correct hypokalemia and hypomagnesemia), hepatotoxicity (liver function tests before initiation, every 2 weeks for first 2 cycles, then monthly), and diarrhea (monitor hydration and electrolyte status). In case of accidental pregnancy exposure, monitor fetal growth and anatomy via ultrasound. |
| Fertility Effects | Based on nonclinical studies, ribociclib may impair female fertility. In male rats, testicular degeneration was observed at exposures comparable to human exposure, suggesting potential impairment of male fertility. In female rats, ovarian effects including reduced corpora lutea and follicular degeneration were observed at clinically relevant exposures. Reversibility not established. |